{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031516","form_type":"8-K","ticker":"PULM","cik":"0001574235","company_name":"Pulmatrix, Inc.","filed_at":"2022-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:51.231904+00:00","generated_at":"2026-06-21T20:09:45.058132+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Pulmatrix reports Q3 2022 revenue $1.9M, net loss $5.05M; PUR1900 Phase 2 on track for Q1 2023","bullets":["Revenues $1.9M, up from $1.1M YoY; net loss $5.05M ($1.45 per share) vs $8.18M loss in prior year.","Cash and equivalents $40.7M; expects to fund ops into Q2 2024; raised $1.4M via ATM at ~$5.70/share.","PUR1900 Phase 2 study for ABPA to start dosing in Q1 2023; 16-week regimen.","PUR3100 Phase 1 data for acute migraine anticipated early Q1 2023; database lock in November.","PUR1800 Phase 1b data analysis ongoing for presentation at 2023 medical conference."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031516","json":"https://secwatch.observer/filing/0001493152-22-031516.json","markdown":"https://secwatch.observer/filing/0001493152-22-031516.md","text":"https://secwatch.observer/filing/0001493152-22-031516.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/0001493152-22-031516-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T20:09:45.058132+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2581e1612ce285d7016da3566a7a5d40bb8c6a6d","claim":"Pulmatrix, Inc. reported the three months ended September 30, 2022 results: revenue $1,872, net income $(5,052), EPS $(1.45) per share.","evidence_excerpt":"PULMATRIX, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited) (in thousands, except share and per share data) Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Revenues $ 1,872 $ 1,069 $ 4,363 $ 4,713 Operating expenses: Research and development 5,287 4,026 13,773 12,423 General and administrative 1,685 1,656 5,212 4,837 Goodwill impairment - 3,577 - 3,577 Total operating expenses 6,972 9,259 18,985 20,837 Loss from operations (5,100 ) (8,190 ) (14,622 ) (16,124 ) Other income (expense), net: Interest income 102 1 118 6 Other (expense) income, net (54 ) 5 (116 ) (22 ) Total other income (expense), net 48 6 2 (16 ) Net loss $ (5,052 ) $ (8,184 ) $ (14,620 ) $ (16,140 ) Net loss per share attributable to common stockholders – basic and diluted $ (1.45 ) $ (2.91 ) $ (4.32 ) $ (6.08 )","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1574235/000149315222031516/0001493152-22-031516-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended September 30, 2022"},{"label":"Revenue","value":"$1,872"},{"label":"Net income","value":"$(5,052)"},{"label":"EPS","value":"$(1.45) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}